Treatment of gastrointestinal stromal tumors with imatinib mesylate: A major breakthrough in the understanding of tumor-specific molecular characteristics

World Journal of Surgery

Volumn 29, Issue 3, 2005, Pages 357-362

  De Mestier, Philippe ^a   Des Guetz, Gaetan ^b  

^a Hopital des Peupliers   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN; IMATINIB; PARACETAMOL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

BLOOD TOXICITY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ENZYME ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL CELL OF CAJAL; INTESTINE MOTILITY; MUSCLE CRAMP; NEUTROPENIA; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 20044378513     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-004-7682-z     Document Type: Conference Paper

References (16)

1. M Miettinen J Lasota 2001 Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis Virchows Arch. 438 1 12
2. S Hirota K Isozaki Y Moriyama 1998 Gain of function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580
3. G des Guetz P de de Mestier 2002 Enfin un traitement efficace dans les sarcomes digestifs indifferencies (tumeurs stromales) J. Chir. 139 268 273
4. DG Savage KH Antman 2002 Imatinib mesylate - a new oral targeted therapy N. Engl. J. Med. 2346 683 693
5. MJ Boudet P de de Mestier 2001 Les tumeurs stromales du tube digestif J. Chir. 138 104 108
6. RP De De Matteo JL Lewis D Leung 2000 Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival Ann. Surg. 231 51 58
7. BEC Plaat H Hollema W Molenaar 2000 Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins J. Ciin. Oncol. 18 3211 3220
8. H Joensuu PJ Roberts SR Maarit 2001 Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor N. Engl. J. Med. 344 1052 1056
9. AT Van Van Oosterom I Judson J Verweij 2001 Safety and efficacy of Imatinib (STI 571) in metastatic gastrointestinal stromal tumors: a phase I study Lancet 358 1421 1423
10. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors N.Engl. Med. 347 472 480
11. MC Heinrich CL Corless C Blanke 2002 Kit mutational status predicts clinical response to STI 571 in patients with metastatic gastrointestinal stromal tumors (GIST) Proc. Am. Soc. Clin. Oncol. 21. Abstr 6
12. CDM Fletcher JJ Berman C Cortess 2002 Diagnosis of gastrointestinal stromal tumors; a consensus approach Hum. Pathol. 33 459 465
13. Blanke CD. Therapeutic options for gastrointestinal stromal tumors. ASCO 2003; Educational Book: 266-272
14. Blay JY, Berthaud P, Perol D et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospectve randomised phase III trial of the French Sarcoma Group. ASCO 2004. Abstr 9006
15. De Matteo, RP et al. ASCO 2003
16. Bertout et al. Guide Pratique Glivec, Novartis oncologie, Rueil Malmaison, France, 2003